IOncology

Editor’s Note: Triple-negative breast cancer (TNBC), characterized by its distinct biology and limited treatment targets, remains one of the most challenging and intensely studied subtypes of breast cancer. At the…

Fifth Bincheng Multidisciplinary Breast Cancer Conference Editor’s Note: The Fifth Bincheng Multidisciplinary Breast Cancer Conference, hosted by the First Affiliated Hospital of Dalian Medical University, was recently held with great…

Hubei Association of Radiation Oncology Physicians 2025 Academic Conference Editor’s Note: The 2025 Annual Academic Conference of the Radiation Oncology Physicians Branch of the Hubei Medical Association was recently held…

The 18th International Conference on Malignant Lymphoma (ICML), organized by the Institute of Oncology Research (IOR), took place from June 17 to 21, 2025, in Lugano, Switzerland. As the most…

At ESMO, Professor Masatoshi Kudo from Kindai University shared results from a matching-adjusted indirect comparison of nivolumab + ipilimumab (CheckMate 9DW) versus durvalumab + tremelimumab (HIMALAYA) and atezolizumab +…

At ESMO, Professor Markus Moehler, Head of the GI Oncology Unit at the University Medical Center Mainz, shared findings from the phase III RATIONAL 305 trial, which evaluated tislelizumab…

Editor’s Note: The 2025 ESMO Gastrointestinal Cancers Congress (ESMO GI), held in Barcelona from July 2–5, brought together leading experts and the latest global advances in GI oncology. Among the…

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.